Loading...
•
Nov 30, 2022
AngioDynamics Q2 2023 Earnings Report
AngioDynamics' Q2 2023 financial results were announced, revealing a sales increase and reaffirmed guidance.
Key Takeaways
AngioDynamics reported a 9.1% increase in net sales to $85.4 million for Q2 2023, with Med Tech sales up 29.7% and Med Device sales up 2.6%. The company's gross margin increased by 100 basis points to 52.8%. GAAP loss per share was $0.21, while adjusted earnings per share was $0.01.
Net sales increased by 9.1% to $85.4 million compared to the prior-year quarter.
Med Tech net sales increased by 29.7% to $24.5 million.
Med Device net sales increased by 2.6% to $60.9 million.
Gross margin increased by 100 basis points year over year to 52.8%.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
Management is reaffirming its previously issued fiscal year 2023 guidance, expecting net sales to be in the range of $342 to $348 million, gross margin to be approximately 52.5% to 54.5% and adjusted earnings per share in the range of $0.01 to $0.06.
Positive Outlook
- Net sales expected to be in the range of $342 to $348 million.
- Gross margin expected to be approximately 52.5% to 54.5%.
- Adjusted earnings per share expected to be in the range of $0.01 to $0.06.
- Continued investment in new product launches.
- Drive future growth.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...